5244702025-04-012025-06-305244702025-06-305244702025-04-012025-06-30in-capmkt:OtherExpenses1Member5244702025-04-012025-06-30in-capmkt:ReportableSegments1Member5244702025-04-012025-06-30in-capmkt:ReportableSegments2Member5244702025-04-012025-06-30in-capmkt:ReportableSegments3Member5244702025-04-012025-06-30in-capmkt:ReportableSegments1Member5244702025-04-012025-06-30in-capmkt:ReportableSegments2Member5244702025-04-012025-06-30in-capmkt:ReportableSegments3Member5244702025-04-012025-06-30in-capmkt:ReportableSegments1Member5244702025-06-30in-capmkt:ReportableSegments1Member5244702025-04-012025-06-30in-capmkt:ReportableSegments2Member5244702025-06-30in-capmkt:ReportableSegments2Member5244702025-04-012025-06-30in-capmkt:ReportableSegments3Member5244702025-06-30in-capmkt:ReportableSegments3Member5244702025-04-012025-06-30in-capmkt:ReportableSegments1Member5244702025-06-30in-capmkt:ReportableSegments1Member5244702025-04-012025-06-30in-capmkt:ReportableSegments2Member5244702025-06-30in-capmkt:ReportableSegments2Member5244702025-04-012025-06-30in-capmkt:ReportableSegments3Member5244702025-06-30in-capmkt:ReportableSegments3Member5244702025-04-012025-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

5244702025-04-012025-06-30

AuditorDomain1

iso4217:INRxbrli:pureiso4217:INRxbrli:shares

524470

SYNCOMF

NOTLISTED

INE312C01025

SYNCOM FORMULATIONS (INDIA) LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2025-08-08

2025-08-02

INR

Lakhs

Quarterly

First quarter

Multi segment

2025-08-08

16:00:00

2025-08-08

16:45:00

Declaration of unmodified opinion

2025-04-01

2025-06-30

Unaudited

Consolidated

1169017000

60347000

1229364000

596130000

156813000

-61248000

159544000

2508000

13400000

159706000

1026853000

202511000

413000

202924000

43250000

2130000

45380000

157544000

40384000

197928000

940000000

0.21

Other Expenses

159706000

Pharmaceuticals Drugs and Formulations

1209995000

Trading of Commodities

10456000

Renting of Properties

8913000

1229364000

Pharmaceuticals Drugs and Formulations

196572000

Trading of Commodities

135000

Renting of Properties

8312000

205019000

2508000

202511000

Pharmaceuticals Drugs and Formulations

3978077000

Trading of Commodities

25918000

Renting of Properties

473344000

4477339000

Pharmaceuticals Drugs and Formulations

843663000

Trading of Commodities

836000

Renting of Properties

13336000

857835000

Notes The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 08 08 2025 These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time The company is operating in 3 segments A Pharmaceuticals Drugs and Formulations B Trading of Commodities C Renting of Property particulars of segment wise results are given as required. As required under Regulation 33 of SEBI LODR Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June 2025. The report does not have any impact on the above results and notes which needs explanation Previous period figures have been regrouped reclassified wherever necessary to confirm to this period classification The Company currently have 3 three Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd Sante Biotech Pvt. Ltd. and Vincit Biotech International Pvt. Ltd.

Items that will be reclassified to profit or loss

40384000

Unaudited

true

Sanjay Mehta & Associates

true

2027-03-31